Highest-materiality recent filing
Coya Therapeutics Q1 net loss $7.2M; cash $50.7M; FDA Fast Track for COYA 302 in ALS
Net loss $7.2M vs $7.3M YoY; R&D expense fell to $4.1M (down $1.1M), G&A rose to $3.4M (up $1.1M).
Howard Berman resigned as Executive Chairman and Board member effective April 1, 2026; part of planned CEO transition initiated November 2024.
Coya Therapeutics FY2025 net loss $21.2M; cash $46.8M, ALS trial enrolling
Cash and cash equivalents $46.8M at Dec 31, 2025; collaboration revenue $7.9M (up from $3.6M).
Coya Therapeutics raises $11.1M via private placement with Dr. Reddy's and Greenlight Capital
Gross proceeds of ~$11.1M from sale of 2,522,727 shares at $4.40 each; no broker/agent.
Coya Therapeutics announces $46.8M cash, runway into H2 2027, ALSTARS readout Q1 2027
Cash balance of $46.8M as of Dec 31, 2025 (unaudited), with projected runway into second half of 2027.
Coya Therapeutics reports positive proof-of-concept study results in Frontotemporal Dementia
9-patient open-label study of low-dose IL-2 + CTLA4-Ig showed no serious adverse events over 22 weeks.
Coya Therapeutics reports Q3 net loss of $2.1M; IND accepted for COYA 302 in ALS
Net loss of $2.1M for Q3 2025 improved from $4.0M loss in Q3 2024; cash and equivalents at $28.1M.
Coya Therapeutics prices upsized public offering of 4.18M shares at $5.50, raising ~$23M
Offering of 3,636,364 shares (base) plus full exercise of 545,454 over-allotment, all at $5.50/share.
Coya Therapeutics receives $4.2M milestone from Dr. Reddy's for ALS IND acceptance
FDA accepted IND for COYA 302 Phase 2 study in ALS, triggering $4.2M milestone from Dr. Reddy's Laboratories.
Coya Therapeutics Q2 2025 net loss $6.1M; cash $29.8M; FDA decision on COYA 302 ALS IND by Aug 29
Net loss $6.1M vs $2.9M in Q2 2024; collaboration revenue fell to $0.2M from $3.4M.
Coya re-submits IND for COYA 302 ALS Phase 2 study after FDA request
Re-submitted IND to FDA on June 30, 2025, including requested non-clinical data.
Coya Therapeutics Q1 net loss $7.3M; pipeline milestones for COYA 302 detailed
Net loss of $7.3M in Q1 2025 vs $5.1M in Q1 2024; R&D expense rose to $5.2M from $3.1M.
Coya Therapeutics FY2024 net loss $14.9M; cash $38.3M; pipeline updates for ALS and FTD trials
Net loss $14.9M in 2024 vs $8.0M in 2023; R&D expenses $11.9M (up from $5.5M).
Coya Therapeutics Q3 net loss $4.0M, cash $39.8M post-raise; positive AD data, new CEO
Net loss $4.0M in Q3 2024 (vs $3.4M prior); cash $31.1M (Sep) rose to $39.8M after capital raise.
Swaminathan employment agreement provides $525,000 base salary, eligible for annual bonus up to 50% of base.
Coya Therapeutics: Phase 2 LD IL-2 in Alzheimer's meets endpoints, shows cognitive stabilization
Study met primary safety endpoint and secondary endpoint for Treg expansion with no off-target effects.
Coya raises $10M via private placement of 1,379,314 shares at $7.25; cash $31M as of Sep 30
1,379,314 shares at $7.25 per share; gross proceeds of ~$10.0M.
Arun Swaminathan, current CBO, promoted to CEO effective Nov 1, 2024; succeeds Howard Berman.
Coya Q2 net loss $2.9M; FDA demands more data before COYA 302 ALS Phase 2
Net loss $2.9M vs $3.1M YoY; collaboration rev $3.4M from Dr. Reddy's.
Submitted IND for Phase 2 double-blind, placebo-controlled study of COYA 302 in ALS on June 14, 2024.
Coya gets $3.85M from Dr. Reddy's for COYA 302 Phase 2 trial; first $6M royalties waived
Dr. Reddy's makes $3.85M one-time payment to Coya for funding first Phase 2 trial of COYA 302 in ALS.
Coya receives $5M strategic investment from ADDF for COYA 302 FTD trial
ADDF purchased 603,136 shares at $8.29/share for $5M gross proceeds in private placement.
Coya Therapeutics Reports Q1 2024 Net Loss of $5.1M and Cash of $36.0M, Advances Pipeline
Net loss was $5.1M for Q1 2024 vs $2.7M in Q1 2023; R&D expenses rose to $3.1M from $1.2M.
Coya Therapeutics reports FY2023 net loss of $8.0M; cash $32.6M plus $7.5M upfront from Dr. Reddy's
Net loss improved to $8.0M in FY2023 from $12.2M in FY2022; R&D spend $5.5M, G&A $7.8M.
Coya Therapeutics reports $32.6M cash at Dec 31, 2023; receives $7.5M from Dr. Reddy's in Jan 2024
Cash and equivalents $32.6M as of Dec 31, 2023; pro forma $40.1M after $7.5M received from Dr. Reddy's in Jan 2024.
Coya partners with Dr. Reddy's on COYA 302 for ALS; raises $26.5M in private placement
Upfront $7.5M from Dr. Reddy's; additional $4.2M upon IND acceptance and $4.2M upon first patient in Phase 2.
Coya Therapeutics Q2 2023 net loss $3.1M; highlights positive AD and ALS clinical data
Net loss of $3.1M ($0.31 per share) for Q2 2023 vs $3.4M loss in Q2 2022.
Coya Therapeutics: Dr. Adrian Hepner resigns as President/CMO, replaced by Dr. Fred Grossman
Dr. Fred Grossman appointed President and CMO effective July 17, 2023, succeeding Dr. Adrian Hepner who resigned.
Coya CEO update: ALS POC shows disease halted 24wks; AD Phase2 data due Q2 2024
COYA 302 in ALS: disease progression halted to week 24 with minimal decline to week 48 on ALSFRS scale in open-label study.
Coya Therapeutics' COYA 301 shows improved cognition and Treg expansion in Phase 1 AD study
8 AD patients treated with monthly COYA 301 (low-dose IL-2) showed statistically significant improvement in MMSE scores (p=0.015) during treatment.
Coya Therapeutics Q1 net loss $2.7M; ALS data halt progression; Dr. Reddy's deal
Net loss of $2.7M ($0.28 per share) for Q1 2023 vs $1.7M loss in Q1 2022.
Coya Therapeutics reports FY2022 net loss of $12.2M; positive ALS data for COYA 302
Net loss of $12.2M for FY2022 vs $4.9M in FY2021; R&D expense rose to $4.4M from $2.5M.
Exclusive License and Supply Agreement with Dr. Reddy's for Abatacept biosimilar, effective April 1, 2023.
Treatment with IL-2/CTLA4-Ig (COYA 302) over 48 weeks significantly increased Treg suppressive function and Treg numbers in 4 ALS patients.
On November 1, 2024, Dr. Hideki Garren provided Coya Therapeutics, Inc. (the “Company”) with notice of his resignation from the Board of Directors, effective immediately.
The Berman Employment Agreement provides for Dr. Berman to serve as Executive Chairman and provides for an annual base salary of $420,000.
Dr. Swaminathan was appointed as the Company’s Chief Executive Officer, effective November 1, 2024.
Dr. Howard Berman, who, on August 16, 2024, notified the Company that he would be resigning as Chief Executive Officer of the Company effective at the close of business on October 31, 2024.
Arun Swaminathan, the Company’s Chief Business Officer since April 2023, will serve as Chief Executive Officer of the Company.
Dr. Swaminathan was also appointed to the Company’s Board as a Class III director to serve until the Company’s 2025 annual meeting of stockholders
After his resignation, Dr. Berman intends to remain a member of the Company’s board of directors (the “Board”) and serve as Executive Chairman of the Board.
On December 19, 2023, the board of directors (the “Board”) of Coya Therapeutics, Inc. (the “Company”) increased the size of the Board to seven directors from six, and appointed Wilbur L. Ross (“Secretary Ross”) as a Class I director to fill the newly created vacancy.
On August 18, 2023, the board of directors (the “Board”) of Coya Therapeutics, Inc. (the “Company”) increased the size of the Board to six directors from five, and appointed Dieter Weinand as a Class I director to fill the newly created vacancy.
Dr. Fred Grossman, who will assume the role of President and Chief Medical Officer as of July 17, 2023
On July 3, 2023, the Company appointed Dr. Fred Grossman President and Chief Medical Officer, effective July 17, 2023.
Dr. Adrian Hepner, the current President and Chief Medical Officer of Coya Therapeutics, Inc. (the “Company”), has informed the Company that he will resign from his position effective July 17, 2023.
Max materiality 0.80 · Median 0.60 · Most common event other_material